Known targets — ChEMBL curated mechanism
POLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PRIM1PRIM2
The experimentally established mechanism targets of Troxacitabine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLA1 known ✓ | P09884 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.60 |
| ▸ | ALB | P02768 | 3/20 | 0.60 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.60 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.60 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.60 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | MTOR | P42345 | 1/20 | 0.53 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.53 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.53 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.53 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.50 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.50 |
| ▸ | POLG | P54098 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.41 |
| ▸ | NT5E | P21589 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Troxacitabine SCHEMBL1026150 | 1.00 | LMNA (0.60) | LMNAPDE3AALBCACNA1FMAPT | |
| Troxacitabine SCHEMBL1026148 | 1.00 | LMNA (0.60) | LMNAPDE3AALBCACNA1FMAPT | |
| Troxacitabine SCHEMBL1653267 | 1.00 | LMNA (0.60) | LMNAPDE3AALBCACNA1FMAPT | |
| Troxacitabine SCHEMBL6424800 | 1.00 | LMNA (0.60) | LMNAPDE3AALBCACNA1FMAPT | |
| Troxacitabine SCHEMBL1844439 | 1.00 | LMNA (0.60) | LMNAPDE3AALBCACNA1FMAPT | |
| Troxacitabine SCHEMBL30317744 | 1.00 | LMNA (0.60) | LMNAPDE3AALBCACNA1FMAPT | |
| Troxacitabine SCHEMBL22285889 | 0.99 | LMNA (0.59) | LMNAPDE3AALBCACNA1FMAPT | |
| Troxacitabine SCHEMBL17542009 | 0.95 | LMNA (0.56) | LMNAPDE3AALBCACNA1FMAPT | |
| Troxacitabine SCHEMBL7560355 | 0.89 | POLG (0.59) | LMNAPDE3AALBCACNA1FMAPT | |
| SCHEMBL31347648 | 0.88 | LMNA (0.59) | LMNAPDE3AALBCACNA1FMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 14469 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144879-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | AI-BIOPHARMA (FR) | 2026-05-28 | — | — | US | claimed |
| EP-4748859-A2 | CHEMICALLY AND PHOTOCHEMICALLY INITIATED CELL MEMBRANE BLEBBING TO INDUCE CELL VESICLE PRODUCTION, MODIFICATIONS THEREOF, AND USES THEREOF | The Regents of the University of California (US) | 2026-05-27 | — | — | EP | claimed |
| EP-4676544-A1 | ANTIBODY-DRUG CONJUGATE COMPRISING ANTIBODIES AGAINST HUMAN L1CAM AND USES THEREOF | LigaChem Biosciences Inc. (KR) | 2026-01-14 | — | — | EP | claimed |
| US-20250268993-A1 | ALKALINE PHOSPHATE-BASED ONCOLOGY TREATMENTS | THERIVA BIOLOGICS, INC. | 2025-08-28 | — | — | US | claimed |
| US-20250242043-A1 | ANTIBODY-DRUG CONJUGATE COMPRISING ANTIBODY AGAINST HUMAN TROP2 AND USE THEREOF | LIGACHEM BIOSCIENCES, INC. (KR) | 2025-07-31 | — | — | US | claimed |
| US-12318434-B2 | Alkaline phosphate-based oncology treatments | THERIVA BIOLOGICS, INC. (US) | 2025-06-03 | — | — | US | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| CN-119584992-A | Antibody-drug conjugates comprising antibodies against human TROP2 and uses thereof | 瑞嘉化学生物科学股份有限公司 | 2025-03-07 | — | — | CN | claimed |
| EP-4504778-A1 | COMBINATION OF A GREMLIN-1 ANTAGONIST WITH A CYTIDINE ANALOGUE OR DEOXYCYTIDINE ANALOGUE | UCB Biopharma SRL (BE) | 2025-02-12 | — | — | EP | claimed |
| EP-4504272-A1 | ANTIBODY-DRUG CONJUGATE COMPRISING ANTIBODY AGAINST HUMAN TROP2 AND USE THEREOF | LigaChem Biosciences Inc. (KR) | 2025-02-12 | — | — | EP | claimed |
| WO-2003076660-A1 | METHOD FOR SELECTING DRUG SENSITIVITY-DETERMINING FACTORS AND METHOD FOR PREDICTING DRUG SENSITIVITY USING THE SELECTED FACTORS | F.HOFFMANN-LA ROCHE AG (CH) | 2003-09-18 | — | — | WO | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| US-20030138864-A1 | Method for identifying an enzyme to design anti-cancer compounds | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-07-24 | — | — | US | claimed |
| EP-1324997-A2 | DIOXOLANE ANALOGS FOR IMPROVED INTER-CELLULAR DELIVERY | Shire Biochem Inc. (CA) | 2003-07-09 | — | — | EP | claimed |
| WO-2003043631-A2 | METHOD FOR IDENTIFICATION OF TUMOR TARGETING ENZYMES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-05-30 | — | — | WO | claimed |
| US-20030013660-A1 | Dioxolane analogs for improved inter-cellular delivery | SHIRE BIOCHEM INC. (CA) | 2003-01-16 | — | — | US | claimed |
| WO-2002030922-A2 | DIOXOLANE ANALOGS FOR IMPROVED INTER-CELLULAR DELIVERY | SHIRE BIOCHEM INC. (CA) | 2002-04-18 | — | — | WO | claimed |
| US-5817667-A | 1-(2-HYDROXYMETHYL-1,3-DIOXOLAN-4-YL)CYTOSINE | UNIVERSITY OF GEORGIA RESEARCH FOUDATION (US) | 1998-10-06 | — | — | US | claimed |
| EP-0781136-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 1997-07-02 | — | — | EP | claimed |
| WO-1996007413-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 1996-03-14 | — | — | WO | claimed |